[go: up one dir, main page]

MX2022014067A - Enzimas con dominios ruvc. - Google Patents

Enzimas con dominios ruvc.

Info

Publication number
MX2022014067A
MX2022014067A MX2022014067A MX2022014067A MX2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A MX 2022014067 A MX2022014067 A MX 2022014067A
Authority
MX
Mexico
Prior art keywords
enzymes
ruvc domains
ruvc
domains
variants
Prior art date
Application number
MX2022014067A
Other languages
English (en)
Inventor
Jason Liu
Christopher Brown
Brian Thomas
Rose Kantor
Audra Devoto
Cristina Butterfield
Lisa Alexander
Daniela S A Goltsman
Greg Cost
Rebecca Lamothe
Diego Espinosa
Meghan Storlie
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of MX2022014067A publication Critical patent/MX2022014067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona enzimas endonucleasas que tienen atributos de dominio distintivos, así como métodos para usar tales enzimas o variantes de las mismas.
MX2022014067A 2020-05-08 2021-05-06 Enzimas con dominios ruvc. MX2022014067A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063022320P 2020-05-08 2020-05-08
US202063032464P 2020-05-29 2020-05-29
US202063116155P 2020-11-19 2020-11-19
US202163180570P 2021-04-27 2021-04-27
PCT/US2021/031136 WO2021226363A1 (en) 2020-05-08 2021-05-06 Enzymes with ruvc domains

Publications (1)

Publication Number Publication Date
MX2022014067A true MX2022014067A (es) 2023-02-22

Family

ID=78468763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014067A MX2022014067A (es) 2020-05-08 2021-05-06 Enzimas con dominios ruvc.

Country Status (10)

Country Link
US (1) US20240209332A1 (es)
EP (2) EP4467642A3 (es)
JP (2) JP7778087B2 (es)
KR (1) KR20230021657A (es)
CN (1) CN116096892A (es)
AU (1) AU2021267379A1 (es)
CA (1) CA3177828A1 (es)
GB (1) GB2612458B (es)
MX (1) MX2022014067A (es)
WO (1) WO2021226363A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
KR102794727B1 (ko) 2020-03-31 2025-04-11 메타지노미, 인크. 클래스 ii, 유형 ii crispr 시스템
BR112023014719A2 (pt) * 2021-01-22 2023-12-05 Metagenomi Inc Novas nucleases quiméricas e manipuladas
CN119452085A (zh) 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
AU2022396533A1 (en) 2021-11-24 2024-05-02 Metagenomi, Inc. Endonuclease systems
CA3243006A1 (en) * 2021-12-21 2025-02-27 Alia Therapeutics Srl TYPE II CAS PROTEINS AND THEIR APPLICATIONS
WO2023137451A1 (en) * 2022-01-14 2023-07-20 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting cd38 and uses thereof
WO2023194359A1 (en) * 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
WO2024056880A2 (en) * 2022-09-16 2024-03-21 Alia Therapeutics Srl Enqp type ii cas proteins and applications thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170175128A1 (en) * 2014-04-18 2017-06-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
AU2016362129A1 (en) * 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
WO2017152015A1 (en) * 2016-03-04 2017-09-08 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
CN116850305A (zh) * 2016-05-06 2023-10-10 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法
WO2018035250A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
CA3058584A1 (en) * 2017-03-30 2018-10-04 Kyoto University Method for inducing exon skipping by genome editing
AU2018367896B2 (en) * 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
CA3085338A1 (en) * 2017-12-11 2019-06-20 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
EP3755792A4 (en) * 2018-02-23 2021-12-08 Pioneer Hi-Bred International, Inc. NEW CASE ORTHOLOGISTS9
EP3775238A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112384621A (zh) * 2018-04-13 2021-02-19 西格马-奥尔德里奇有限责任公司 使用成对的crispr切口酶核糖核蛋白修饰免疫相关基因组基因座
KR20210091160A (ko) * 2018-10-16 2021-07-21 인텔리아 테라퓨틱스, 인크. 면역요법을 위한 조성물 및 방법
EP3924482A4 (en) * 2019-02-14 2023-04-05 Metagenomi, Inc. ENZYMES WITH RUVC DOMAINS
KR20230157387A (ko) * 2021-03-19 2023-11-16 메타지노미, 인크. Cas 효소를 이용한 다중 편집

Also Published As

Publication number Publication date
EP4146800A1 (en) 2023-03-15
US20240209332A1 (en) 2024-06-27
CA3177828A1 (en) 2021-11-11
CN116096892A (zh) 2023-05-09
JP2025090617A (ja) 2025-06-17
JP7778087B2 (ja) 2025-12-01
JP2023533417A (ja) 2023-08-03
WO2021226363A1 (en) 2021-11-11
AU2021267379A1 (en) 2022-12-08
GB2612458B (en) 2025-04-09
EP4467642A3 (en) 2025-04-16
KR20230021657A (ko) 2023-02-14
GB202217378D0 (en) 2023-01-04
EP4467642A2 (en) 2024-11-27
GB2612458A (en) 2023-05-03

Similar Documents

Publication Publication Date Title
MX2022014067A (es) Enzimas con dominios ruvc.
GB2605340A8 (en) Base editing enzymes
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
WO2022232638A3 (en) Enzymes with ruvc domains
MX2021009886A (es) Enzimas con dominios ruvc.
MX2024005505A (es) Enzimas de edicion de bases.
WO2020252229A3 (en) Inhibitors of sarm1
EP4328241A3 (en) Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
EP3882343A3 (en) Thermostable variants of t7 rna polymerase
MX2016001315A (es) Variantes de enzimas.
CR20230113A (es) Inhibidores de sarm1
WO2018160995A8 (en) COMPOSITION AND METHODS FOR ENHANCED MICROBIAL DIGESTION OF POLYMERS IN HYDRAULIC FRACTURING WELLS
WO2020051375A3 (en) Papd5 inhibitors and methods of use thereof
MY189867A (en) Solubilization of msw with blend enzymes
PH12021550558A1 (en) Modulators of pnpla3 expression
EP4309732A3 (en) Modulators of pcsk9 expression
MX2010005395A (es) Metodo para tratar artritis.
WO2017076421A9 (en) Solubilization of msw with blend enzymes
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
MX2024002539A (es) Enzimas con dominios ruvc.
GB2615901A8 (en) Base editing enzymes
PH12020551995A1 (en) Modulator of apol1 expression
ZA202105742B (en) Modulators of malat1 expression
MY206015A (en) Modulators of irf4 expression
MX2024014079A (es) Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos